Literatur

1. Musunuru HB et al. Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience. ASCO Genitourinary Cancers Symposium 2015, Abstract #163.
2. Flaig TW et al. Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. ASCO Genitourinary Cancers Symposium 2015, Abstract #152
3. Antonarakis ES et al. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO Genitourinary Cancers Symposium 2015, Abstract #138.
4. Riggin AJ, Siddiqui MM. Development of intermediate and high-risk prostate cancer after testicular cancer. ASCO Genitourinary Cancers Symposium 2015, Abstract #177.
5. Klepp OH et al. Overall survival (OS) in renal cell carcinoma (RCC) before and after the introduction of targeted therapies (TTs): A Norwegian population-based study (2000–2011). ASCO Genitourinary Cancers Symposium 2015, Abstract #443.
6. Lee JL et al. Randomized phase II trial of sunitinib four-week on and two-week off versus two-week on and one-week off in metastatic clear cell type renal cell carcinoma: RESTORE trial. ASCO Genitourinary Cancers Symposium 2015, Abstract #427
7. Keizman D et al. Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC). ASCO Genitourinary Cancers Symposium 2015, Abstract #429
8. Haas NB, Manola J, Uzzo RG, et al. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. ASCO Genitourinary Cancers Symposium 2015, Abstract #403.
9. Thomas AZ et al. Surgical management for local retroperitoneal recurrence after radical nephrectomy in the targeted therapy era. ASCO Genitourinary Cancers Symposium 2015, Abstract #431
10. O´Donnell PH et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. ASCO Genitourinary Cancers Symposium 2015, Abstract #296.
11. Kim JW et al. Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. ASCO Genitourinary Cancers Symposium 2015, Abstract #297.